5 results on '"Anouk Stam"'
Search Results
2. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model
- Author
-
Sarah B Thomson, Anouk Stam, Cynthia Brouwers, Valentina Fodale, Alberto Bresciani, Michael Vermeulen, Sara Mostafavi, Terri L Petkau, Austin Hill, Andrew Yung, Bretta Russell-Schulz, Piotr Kozlowski, Alex MacKay, Da Ma, Mirza Faisal Beg, Melvin M Evers, Astrid Vallès, and Blair R Leavitt
- Subjects
Neurology (clinical) - Abstract
Huntingtin (HTT)-lowering therapies show great promise in treating Huntington’s disease. We have developed a microRNA targeting human HTT that is delivered in an adeno-associated serotype 5 viral vector (AAV5-miHTT), and here use animal behaviour, MRI, non-invasive proton magnetic resonance spectroscopy and striatal RNA sequencing as outcome measures in preclinical mouse studies of AAV5-miHTT. The effects of AAV5-miHTT treatment were evaluated in homozygous Q175FDN mice, a mouse model of Huntington’s disease with severe neuropathological and behavioural phenotypes. Homozygous mice were used instead of the more commonly used heterozygous strain, which exhibit milder phenotypes. Three-month-old homozygous Q175FDN mice, which had developed acute phenotypes by the time of treatment, were injected bilaterally into the striatum with either formulation buffer (phosphate-buffered saline + 5% sucrose), low dose (5.2 × 109 genome copies/mouse) or high dose (1.3 × 1011 genome copies/mouse) AAV5-miHTT. Wild-type mice injected with formulation buffer served as controls. Behavioural assessments of cognition, T1-weighted structural MRI and striatal proton magnetic resonance spectroscopy were performed 3 months after injection, and shortly afterwards the animals were sacrificed to collect brain tissue for protein and RNA analysis. Motor coordination was assessed at 1-month intervals beginning at 2 months of age until sacrifice. Dose-dependent changes in AAV5 vector DNA level, miHTT expression and mutant HTT were observed in striatum and cortex of AAV5-miHTT-treated Huntington’s disease model mice. This pattern of microRNA expression and mutant HTT lowering rescued weight loss in homozygous Q175FDN mice but did not affect motor or cognitive phenotypes. MRI volumetric analysis detected atrophy in four brain regions in homozygous Q175FDN mice, and treatment with high dose AAV5-miHTT rescued this effect in the hippocampus. Like previous magnetic resonance spectroscopy studies in Huntington’s disease patients, decreased total N-acetyl aspartate and increased myo-inositol levels were found in the striatum of homozygous Q175FDN mice. These neurochemical findings were partially reversed with AAV5-miHTT treatment. Striatal transcriptional analysis using RNA sequencing revealed mutant HTT-induced changes that were partially reversed by HTT lowering with AAV5-miHTT. Striatal proton magnetic resonance spectroscopy analysis suggests a restoration of neuronal function, and striatal RNA sequencing analysis shows a reversal of transcriptional dysregulation following AAV5-miHTT in a homozygous Huntington’s disease mouse model with severe pathology. The results of this study support the use of magnetic resonance spectroscopy in HTT-lowering clinical trials and strengthen the therapeutic potential of AAV5-miHTT in reversing severe striatal dysfunction in Huntington’s disease.
- Published
- 2022
3. Widespread and sustained target engagement in Huntington’s disease minipigs upon intrastriatal microRNA-based gene therapy
- Author
-
Carlos Vendrell-Tornero, Astrid Vallès, Seyda Acar-Broekmans, Roman Liscak, Cynthia Brouwers, Lieke Paerels, Pavlina Konstantinova, Melvin M. Evers, Jan Motlik, Marina Sogorb-Gonzalez, Jiri Klima, Harald Petry, Bas Blits, Anouk Stam, Roberta Pintauro, Zdenek Starek, Michal Crha, Dušan Urgošík, Valentina Fodale, Bozena Bohuslavova, Alberto Bresciani, Zdenka Ellederova, and Sander J. H. van Deventer
- Subjects
Huntingtin Protein ,Huntingtin ,Swine ,business.industry ,Genetic enhancement ,Putamen ,Genetic Vectors ,Neurodegeneration ,Genetic Therapy ,General Medicine ,Striatum ,Pharmacology ,medicine.disease ,Viral vector ,Disease Models, Animal ,MicroRNAs ,Huntington Disease ,Cerebrospinal fluid ,Huntington's disease ,medicine ,Animals ,Humans ,Swine, Miniature ,Tissue Distribution ,business - Abstract
Huntingtin (HTT)-lowering therapies hold promise to slow down neurodegeneration in Huntington's disease (HD). Here, we assessed the translatability and long-term durability of recombinant adeno-associated viral vector serotype 5 expressing a microRNA targeting human HTT (rAAV5-miHTT) administered by magnetic resonance imaging-guided convention-enhanced delivery in transgenic HD minipigs. rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls. Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions. Vector DNA presence and transgene expression were similar at 6 and 12 months after administration. Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions. Translational pharmacokinetic and pharmacodynamic measures in cerebrospinal fluid (CSF) were largely in line with the effects observed in the brain. CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing. This study demonstrates widespread biodistribution, strong and durable efficiency of rAAV5-miHTT in disease-relevant regions in a large brain, and the potential of using CSF analysis to determine vector expression and efficacy in the clinic.
- Published
- 2021
4. Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system
- Author
-
Pavlina Konstantinova, Martin de Haan, Anouk Stam, Astrid Vallès, Carlos Vendrell-Tornero, Rienk Nieuwland, Sander J. H. van Deventer, Elisabeth A. Spronck, Sonay Keskin, Melvin M. Evers, Jolanda Snapper, Jana Miniarikova, Marina Sogorb-Gonzalez, Laboratory for Experimental Clinical Chemistry, ACS - Microcirculation, and 01 Internal and external specialisms
- Subjects
0301 basic medicine ,Huntingtin ,microRNA ,AcademicSubjects/SCI01870 ,Genetic enhancement ,General Engineering ,Biology ,Viral vector ,03 medical and health sciences ,Gene therapy ,spinocerebellar ataxia ,030104 developmental biology ,0302 clinical medicine ,huntington disease ,Extracellular ,Cancer research ,AcademicSubjects/MED00310 ,Original Article ,Secretion ,extracellular vesicles ,Induced pluripotent stem cell ,Gene ,030217 neurology & neurosurgery - Abstract
The preclinical development of microRNA-based gene therapies for inherited neurodegenerative diseases is accompanied by translational challenges. Due to the inaccessibility of the brain to periodically evaluate therapy effects, accessible and reliable biomarkers indicative of dosing, durability and therapeutic efficacy in the central nervous system are very much needed. This is particularly important for viral vector-based gene therapies, in which a one-time administration results in long-term expression of active therapeutic molecules in the brain. Recently, extracellular vesicles have been identified as carriers of RNA species, including microRNAs, and proteins in all biological fluids, whilst becoming potential sources of biomarkers for diagnosis. In this study, we investigated the secretion and potential use of circulating miRNAs associated with extracellular vesicles as suitable sources to monitor the expression and durability of gene therapies in the brain. Neuronal cells derived from induced pluripotent stem cells were treated with adeno-associated viral vector serotype 5 carrying an engineered microRNA targeting huntingtin or ataxin3 gene sequences, the diseases-causing genes of Huntington disease and spinocerebellar ataxia type 3, respectively. After treatment, the secretion of mature engineered microRNA molecules was confirmed, with extracellular microRNA levels correlating with viral dose and cellular microRNA expression in neurons. We further investigated the detection of engineered microRNAs over time in the CSF of non-human primates after a single intrastriatal injection of adeno-associated viral vector serotype 5 carrying a huntingtin-targeting engineered microRNA. Quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion. Altogether, these results confirm the long-term expression of adeno-associated viral vector serotype 5-delivered microRNAs and support the use of extracellular vesicle-associated microRNAs as novel translational pharmacokinetic markers in ongoing clinical trials of gene therapies for neurodegenerative diseases., Graphical Abstract Graphical Abstract
- Published
- 2021
5. When your dream job can become a nightmare – Midwives’ reports of work-related traumatic events: a mixed-methods study
- Author
-
Hester Duivis, Yvonne Fontein-Kuipers, Verena Schamper, Diana Koster, Anouk Stam, and Veerle Schmitz
- Subjects
medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,Event (computing) ,Birth trauma ,Traumatic stress ,Obstetrics and Gynecology ,Personal life ,Timeline ,medicine.disease ,Work related ,03 medical and health sciences ,0302 clinical medicine ,Compassion fatigue ,Content analysis ,Family medicine ,Maternity and Midwifery ,Pediatrics, Perinatology and Child Health ,medicine ,030212 general & internal medicine ,Psychology - Abstract
Introduction There is limited evidence of the effect and impact on midwives of being involved or witnessing traumatic work-related events. We categorised midwives' selfreported traumatic work-related events and responses to an event and explored the impact on the midwives' professional and personal life. Methods A sequential explanatory mixed-methods study, consisting of a questionnaire and semi-structured interviews for midwives who practised or who had practised in the Netherlands or Flanders. Results In total, 106 questionnaires were completed. We categorised various workrelated traumatic events: witnessing birth trauma/complications (34%), death (28.3%), (mis)management of care (19.8%), events related to the perceived social norm of maternity services' practitioners (9.5%), events related to environmental and contextual issues (5.6%) and to (mis)communication (2.8%). Sharing the experience with colleagues, family and friends, a supervisor or the woman involved in the event, was the most common response. In all, 74.5% of the participants still experienced the influence of work-related events in day-to-day practice and 37.5% still experienced the effects in their personal life. The scores of three participants (3.2%) indicated the likelihood of post-traumatic stress. Twenty-four interviews were conducted. Four themes emerged from the content analysis: 1) Timeline, 2) Drawing up the balance of relations with others, 3) Fretting and worrying, and 4) Lessons learned. Conclusions Various work-related traumatic events can impact on midwives' professional and/or personal life. Although not all midwives reported experiencing (lasting) effects of the events, the impact was sometimes far-reaching. Therefore, midwives' experiences and impact of work-related traumatic events cannot be ignored in midwifery practice, education and in supervision or mentoring.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.